My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

52.45 -0.39 (-0.73%)
Streaming Delayed Price Updated: 12:23 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metsera, Inc. - Common Stock

< Previous 1 2 3 Next >
Gold Gains Over 1%; Quantum Computing Shares Plunge
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up
Via Stocktwits
Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal
The deal follows two high-profile failures for Pfizer, which is trying to broaden its small pipeline in weight loss. 
Via Investor's Business Daily
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to its pipeline. 
Via Benzinga
Monday's pre-market session: top gainers and losers
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
MTSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Metsera, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market
Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs. 
Via Benzinga
Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details
The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday. 
Via Stocktwits
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
From Pfizer Inc.
Via Business Wire
Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
From Metsera, Inc.
Via GlobeNewswire
Metsera to Present at Upcoming September Investor Conferences
From Metsera, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress
From Metsera, Inc.
Via GlobeNewswire
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
From Metsera, Inc.
Via GlobeNewswire
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36. 
Via Stocktwits
Topics Government
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans. 
Via Benzinga
Crude Oil Moves Higher; Graham Shares Surge After Q4 Results
 
Via Benzinga
Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.